Keywords: FDA, Amgen, Denosumab, Prolia, Bone metastases, GlaxoSmithKline, Priority review

FDA Grants priority review for Amgen’s denosumab BLA for the reduction of skeletal-related events in advanced cancer patients

Article | 19 July 2010

Print This

The US Food and Drug Administration has granted priority review designation to biotechnology major Amgen’s denosumab, a subcutaneous RANK ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in